About Us

Management Team

Proven executive & research team at the forefront of aging-based science and clinical research

 
Jerry McLaughlin
Chief Executive Officer
Jerry McLaughlin
Jerry McLaughlin
Chief Executive Officer

Jerry McLaughlin is chief executive officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as president and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of senior vice president & chief commercial officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.

 
Jennifer Cermak, PhD
Senior Vice President
Clinical Development
Jennifer Cermak, PhD
Jennifer Cermak, PhD
Senior Vice President
Clinical Development

A seasoned leader in the research and development, Dr. Jennifer Cermak has over two decades of related experience. She has demonstrated success co-founding life science companies with the completion of two IPOs, one series C, two series B financing, and 11 Series A financing rounds. Having co-founded biotech start-ups and managed R&D for multiple biotechnology startup companies, Dr. Cermak has quickly built company value successfully leading every aspect of the production of life-changing pharmaceuticals from start to finish and brought them to market. She has broad-based therapeutic knowledge conducting over 50 Phase 1-4 trials for drugs, supplement, device, and biologics. She is a results-oriented leader who effectively leads complex life science programs. She holds a PhD in pathology from Boston University School of Medicine, and she completed her postdoctoral fellowship in the Department of Surgery at Harvard Medical School.

 
Tristan Edwards
Co-Founder
Tristan Edwards
Tristan Edwards
Co-Founder

Tristan Edwards is co-founder, president, and chief investment officer of Life Biosciences. He also sits on the boards of Continuum Biosciences, Animal Biosciences, Senolytic Therapeutics, and Jumpstart Fertility. Tristan brings extensive global financial capital markets, regulatory compliance, and fiduciary oversight experience to the group, following a 16-year investment career spanning leading financial organizations across Australia, London, Hong Kong, and Singapore. Having recognized the opportunity to leverage this experience in an entrepreneurial environment, he has subsequently moved to pursue his passion for helping create a scalable platform for financing and enabling the world’s best scientists and thought leaders to create change. Tristan’s professional background has been in senior investment roles at leading financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital, and Mosaic Asset Management. He started his career with the Australian Commonwealth Department of Finance. Tristan has a degree in commerce from the University of Tasmania and held the CFA, CMT, and CPA designations.

 
Amit Shashank
General Counsel
Amit Shashank
Amit Shashank
General Counsel

Amit Shashank is a strategically oriented global leader, with more than 20 years of international experience in technology and business services organizations. As general counsel, he oversees Life Biosciences’ government affairs, legal, and compliance initiatives. Amit is a leader in navigating complex regulatory approvals and developing global strategic alliances that span mergers and acquisitions, commercial transactions, and all phases of corporation financings. On two separate occasions, Amit has led companies toward commercializing and liquidity events which include initial public offerings (IPO). Most recently, Amit served as executive vice president, general counsel, and secretary of Aricent, a global R&D engineering and design powerhouse, which under his leadership as part of the executive team, grew to over 10,000 employees. In 2018, Amit was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies (EPA: ALT) for $2 billion. Prior to Aricent, Amit served as executive vice president, general counsel, chief compliance officer, and secretary at ExlService Holdings, Inc. (NASDAQ: EXLS), an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company. Amit began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law. Amit is also a Rhodes Scholar and an adjunct professor at Columbia University Law School.

 
Bill Sullivan
Chief Financial Officer
Bill Sullivan
Bill Sullivan
Chief Financial Officer

With more than 25 years of experience in corporate finance, strategic transactions, fundraising, and investor relations, Bill Sullivan joins Life Biosciences as chief financial officer. He was previously chief financial officer and treasurer at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led multiple financings and core business and finance functions. Prior to AGTC, he worked at Merrimack Pharmaceuticals, Inc. for 10 years and held a variety of important leadership positions including chief financial officer. At Merrimack, he led the company’s $100 million initial public offering, helped the company raise over $400 million in debt and equity capital as a public company, and played a key role in Merrimack’s asset sale to Ipsen SA for up to $1.025 billion. Prior to his role at Merrimack, Bill worked for a number of years in the high-technology sector. He holds a BA in economics from Williams College and an MBA and MS in accounting from Northeastern University and obtained his certified public accountant license while working at Arthur Andersen, LLP.